Intellectual Property Rights

Monsanto Technology LLC v. Nuziveedu Seeds Ltd.

(2019) 3 SCC 381

Facts

Monsanto owned an Indian patent concerning a synthetic nucleic-acid sequence used to create insect-resistant cotton plants.
The technology allowed cotton plants to produce a toxin harmful to bollworms and was commercially associated with Bt cotton.
Monsanto licensed the technology to Indian seed companies, including Nuziveedu Seeds.
The licensees incorporated the trait into hybrid cotton seeds and paid contractual trait fees.
A dispute arose regarding the amount of trait fees and regulatory price controls.
Monsanto terminated the licences and sued for:
patent infringement;
trademark infringement;
contractual relief.
Nuziveedu challenged the patent and argued that the subject matter was excluded by Section 3(j), which concerns plants, seeds and essentially biological processes.
At an interim stage, the Delhi High Court Division Bench held the patent invalid and directed Monsanto toward protection under the plant-variety regime.
Monsanto appealed to the Supreme Court.

Whether the Delhi High Court could finally decide patent validity at a preliminary stage.
Whether Monsanto’s nucleic-acid claim was excluded under Section 3(j).
Whether the dispute required evidence and a full trial.
What interim arrangement should govern the parties while the suit continued.

Patent validity may be challenged through a counterclaim and relevant statutory defences.
Complex questions concerning:
claim construction;
biotechnology;
Section 3(j);
distinction between a patented component and a plant or seed;
interaction with plant-variety legislation ordinarily require pleadings, expert evidence and trial.
A court deciding interim relief should not finally revoke a patent without following the statutory procedure and allowing proper evidence.
An appellate court should avoid conclusively deciding disputed scientific facts that the trial court has not examined.
The grant of a patent does not make it unchallengeable, but invalidity must be judicially determined through proper proceedings.

Monsanto’s claim was framed around a particular man-made nucleic-acid sequence and related constructs.
Nuziveedu argued that once incorporated into cotton seed, the technology became part of a plant and fell within Section 3(j).
Monsanto argued that the patented invention existed before incorporation and remained a human-made biotechnology product.
Resolving that conflict required a detailed understanding of:
what precisely the claims covered;
how the sequence functioned;
whether the claimed subject matter was itself a plant or seed;
how the technology reproduced through plant generations;
the scope of the statutory exclusion.
The Division Bench had determined these matters largely at the interim stage.
The Supreme Court held that this was procedurally and substantively premature.
Neither party had yet presented the full expert evidence needed for a final decision.
The Court therefore refused to endorse either side’s ultimate interpretation of Section 3(j).
It restored the patent suit and Nuziveedu’s counterclaim for invalidity.
The earlier interim arrangement governing use of the technology and payment obligations was also restored, subject to further trial-court orders.
The judgment is frequently misunderstood.
The Supreme Court did not finally hold that Monsanto’s patent was valid.
It held that validity could not be conclusively rejected without a proper trial.

The Supreme Court set aside the Division Bench’s final conclusions on patent invalidity.
Monsanto’s infringement suit and Nuziveedu’s revocation counterclaim were restored for trial.
The Court left the Section 3(j) and validity questions open.
Use this case for: a complex biotechnology patent cannot be finally invalidated at an interim stage without claim construction, expert evidence and a full statutory trial.